Last update 23 Jan 2025

3HP-2827

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2000 (3H Pharmaceuticals)
+ [1]
Target
FGFR2
Mechanism
FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists)
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid NeoplasmFGFR2 Mutation Solid TumorsFGFR2 Mutant Neoplasms
Inactive Indication-
Originator Organization
3H (Suzhou) Pharmaceuticals Co., Ltd
Active Organization
3H (Suzhou) Pharmaceuticals Co., Ltd3H (Shanghai) Pharmaceuticals Co., Ltd3H (Shanghai) Pharmaceuticals Co., Ltd
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Related

3
Clinical Trials associated with 3HP-2827
NCT06287918
/ Not yet recruitingPhase 1
A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06378593
/ RecruitingPhase 1/2
An Open-Label, Multi-center Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
CTR20241063
/ RecruitingPhase 1/2
3HP-2827在FGFR2异常的手术不可切除/转移性实体瘤患者中的安全性、耐受性、药代动力学和疗效的开放、多中心1/2期临床研究
[Translation] An open-label, multicenter Phase 1/2 clinical study of the safety, tolerability, pharmacokinetics, and efficacy of 3HP-2827 in patients with surgically unresectable/metastatic solid tumors with FGFR2 abnormalities
100 Clinical Results associated with 3HP-2827
Login to view more data
100 Translational Medicine associated with 3HP-2827
Login to view more data
100 Patents (Medical) associated with 3HP-2827
Login to view more data
100 Deals associated with 3HP-2827
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
CN
3H (Suzhou) Pharmaceuticals Co., Ltd
17 Jun 2024
FGFR2 Mutation Solid TumorsPhase 2
CN
3H (Suzhou) Pharmaceuticals Co., Ltd
17 Jun 2024
FGFR2 Mutant NeoplasmsPhase 2
CN
3H (Suzhou) Pharmaceuticals Co., Ltd
06 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free